Orchestra BioMed Holdings, Inc.

What they do

Orchestra BioMed develops late-stage therapeutic device candidates, principally AVIM Therapy, a firmware-based bioelectronic hypertension treatment delivered through cardiac pacemakers, and Virtue SAB, a non-coated sirolimus drug delivery angioplasty balloon. It runs pivotal trials, including the BACKBEAT global study with Medtronic and the Virtue Trial versus Boston Scientific's AGENT drug-coated balloon, while relying on partners for commercialization. The company also has a subsidiary, FreeHold Surgical, which has provided limited product revenue.

Revenue drivers

• AVIM Therapy (Medtronic collaboration) — Pre-commercial; no approved product revenue yet. Under the 2022 Medtronic Agreement, Medtronic supports development and would hold exclusive global commercialization rights for AVIM Therapy in pacemaker-indicated hypertension patients, with Orchestra sharing in resulting revenues.
• Virtue SAB — Pre-commercial; investigational device in the U.S. IDE Virtue Trial randomizing against Boston Scientific's AGENT drug-coated balloon, with no product revenue reported.
• FreeHold Surgical — Subsidiary described as the source of limited product revenue, a small portion of total reported revenue relative to collaboration and financing inflows.
• Collaboration, royalty and financing inflows — Reported revenue includes non-product items such as collaboration support, royalty purchase proceeds and strategic investment sales; the $33.5M in 2025 revenue versus $2.6M in 2024 indicates revenue is lumpy and event-driven rather than recurring product sales.

Recent performance

Reported revenue was $33.5M in 2025 versus $2.6M in 2024, with quarterly revenue swinging from $30.9M in Q4 2025 to $110,000 in Q1 2026 and $88,000 in Q2 2026. Net loss was $52.7M in 2025, down from $61.0M in 2024, and $44.4M for the six months ended June 30, 2026 versus $38.1M a year earlier. Operating cash use was $49.0M in 2025, and the company had $110.0M in cash, cash equivalents and marketable securities at June 30, 2026 ($20.5M cash plus $89.5M marketable securities), total liabilities of $86.3M, and shareholders' equity of $19.3M. Accumulated deficit reached $407.0M as of June 30, 2026.

Strategy

Management's stated strategy is a partnership-enabled model: develop late-stage device candidates, then hand off global commercialization to market-leading device companies in exchange for development support and revenue sharing. For AVIM Therapy, the company and Medtronic amended their collaboration in August 2025 to allow potential integration into future Medtronic leadless pacemakers, alongside an $11.6M additional Medtronic equity investment and a $20M commitment. For Virtue SAB, Orchestra is running a 740-patient U.S. IDE pivotal trial versus Boston Scientific's AGENT balloon. The company funds operations through equity issuances, debt, royalty sales and strategic investment sales, and expects continued significant losses.

Risks

• Clinical trial execution and timing — BACKBEAT enrollment completion has moved from mid-2026 (10-K) to end of Q3 2026 (10-Q), and the Virtue Trial's 740-patient enrollment is now planned for 2027, so delays could defer any revenue.
• No approved products — Both flagship candidates remain investigational, and the 10-K states safety and efficacy have not been established by any regulatory body.
• Partner dependence — AVIM Therapy commercialization depends on Medtronic, which holds exclusive global rights for the pacemaker-indicated hypertension population; loss or delay of that collaboration would remove the main path to market.
• Cash burn and financing needs — The company incurred net losses of $44.4M in the first half of 2026 alone and had $110.0M in cash plus marketable securities at June 30, 2026 against an accumulated deficit of $407.0M, so it will require additional capital.

Outlook

Management targets completing BACKBEAT Trial enrollment by the end of the third quarter of 2026, with the company and Medtronic intending, if primary endpoints are met, to present primary endpoint data at a major cardiovascular conference in the second quarter of 2027 followed by FDA and global marketing submissions. The Virtue Trial is expected to complete enrollment in 2027. The company states it expects to continue incurring significant losses for the foreseeable future and may borrow additional funds under current debt arrangements.